pemetrexed / Generic mfg. - LARVOL DELTA

Induction Pemetrexed Salvage Chemotherapy for Advanced Differentiated and Anaplastic Thyroid Cancer: An Expanded Mayo Clinic Cohort (ATA 2026) - No abstract available

Metastases • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma

MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial (ESMO 2022) - P1 | "Conclusions M1500+C improved DOR, PFS and OS compared to P+C in a randomized signal finding trial in 1L Nsq NSCLC. Emerging data with M750+C shows similarly encouraging efficacy, especially in PD-L1<1% subgroup, with improved tolerability."

Late-breaking abstract • P1/2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Volrustomig as Single-Agent First-Line Therapy for Unresectable Pleural Mesothelioma: Substudy 5 of eVOLVE-02 Phase 2 Study (IASLC-WCLC 2026) - P2 | "Nivolumab + ipilimumab and pembrolizumab + pemetrexed + platinum chemotherapy showed improved survival vs chemotherapy alone, with greater benefit in non-epithelioid compared to epithelioid pleural mesothelioma. eVOLVE-02 is recruiting patients; 3 substudies are ongoing in cervical cancer and head and neck squamous cell carcinoma. Substudy 5 enrollment is planned at sites in 8 countries/regions: Australia, Canada, China, Germany, Italy, Taiwan, UK, and USA."

Clinical • P2 data • Cervical Cancer • Epithelioid Pleural Mesothelioma • Head and Neck Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Pleural Mesothelioma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS (AACR 2025) - P2 | "In Cohort 1, participants must not have received any prior systemic therapy and will receive SC amivantamab and oral lazertinib; in Cohort 2, participants must have had disease progression after EGFR-TKI monotherapy and will receive SC amivantamab and chemotherapy (carboplatin-pemetrexed). COPERNICUS aims to evaluate the efficacy and safety of SC amivantamab regimens using a pragmatic study design to enroll participants with diverse backgrounds and combine advancements in supportive care to prevent and proactively manage AEs."

Clinical • P2b data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR-mutated advanced NSCLC: Interim results. (ASCO 2026) - P2 | "Funded by Janssen Research & Development, LLC, a Johnson & Johnson company Clinical Trial Registration Number: NCT06667076 Background: In MARIPOSA-2, intravenous ami + carboplatin-pemetrexed chemo significantly prolonged progression-free survival (PFS) vs chemo (HR, 0.48; P<0.001) in participants (pts) with EGFR-mutated (exon 19 deletion [Ex19del]/L858R) advanced NSCLC after progression on osimertinib. Compared with MARIPOSA-2, SC ami and dermatologic prophylaxis in COPERNICUS led to substantial reductions in ARRs, dermatologic AEs, and ami interruptions, establishing the positive effect of early supportive care interventions. These interim data obtained using a pragmatic design support wide use of SC ami Q3W + chemo post-EGFR TKI progression in a diverse population."

Adverse events • Metastases • P2b data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2 (IASLC-WCLC 2025) - P2 | "Introduction : Intravenous amivantamab plus chemotherapy (carboplatin-pemetrexed)is approved for first-line treatment of patients with EGFR exon 20 insertion(Ex20ins)-mutated advanced non-small cell lung cancer (NSCLC), based on the resultsof the PAPILLON study. Discontinuationof amivantamab due to treatment-related AEs was 12%. Conclusions : Among participants with EGFR Ex20ins-mutatedadvanced NSCLC, first-line treatment with subcutaneous amivantamab Q3W plus chemotherapydemonstrated a response rate and safety profile consistent with historical intravenousamivantamab Q3W data, with a reduced incidence of ARRs."

Clinical • EGFR exon 20 • Metastases • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Preliminary results from two single-center phase I studies of intrathecal PD-1/CTLA-4 antibody combined with pemetrexed for leptomeningeal metastases from solid tumors (EANO 2026) - P1/2 | "Cadonilimab (AK104) and iparomlimab/tuvonralimab (QL1706) are novel bispecific PD-1/CTLA‑4 antibody. The study demonstrates the manageable safety and feasibility of IT PD-1/CTLA-4 antibody combined with PM, with no unexpected systemic or neurological toxicities observed. Preliminary results suggest potential clinical benefits, with a high clinical response rate and notable treatment responses even among those with severe conditions. ClinicalTrials.gov registration: NCT06762080/ NCT06809530."

Clinical • P1 data • Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study. (PubMed, Ann Oncol) - "Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved progression-free survival and intracranial progression-free survival versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen."

Journal • Metastases • P3 data • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

First-line Amivantamab-chemotherapy vs Chemotherapy in NSCLC with EGFR Exon 20 Insertions: Overall Survival from PAPILLON (IASLC-WCLC 2026) - P3 | "In the phase 3 PAPILLON study (NCT04538664; median follow-up: 14.9 months), first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) significantly improved median progression-free survival by blinded independent central review (BICR) versus chemotherapy (11.4 vs 6.7 months; HR, 0.40; 95% CI, 0.30-0.53; P <0.001) in participants with Ex20ins advanced NSCLC (Zhou NEJM 2023). OS was extended by a clinically meaningful 6 months with amivantamab-chemotherapy versus chemotherapy (34.3 vs 27.9 months) despite extensive (76%) subsequent amivantamab use in the chemotherapy arm. While crossover likely attenuated the HR-based OS estimate, the adjusted OS analysis showed a substantially longer estimated survival benefit, supporting amivantamab-chemotherapy as a foundational first-line regimen for patients with Ex20ins advanced NSCLC."

Clinical • EGFR exon 20 • Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study (ESMO 2023) - P3 | "Ami combined with carboplatin/pemetrexed (ami-chemo) demonstrated safety and antitumor activity in the phase 1 CHRYSALIS study. Safety profile was consistent with that of each individual agent. PAPILLON establishes ami-chemo as the new first-line standard of care in EGFR Ex20ins advanced NSCLC."

Clinical • EGFR exon 20 • Late-breaking abstract • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC (IASLC-WCLC 2022) - P1 | " The LACP (lazertinib, amivantamab, carboplatin, pemetrexed) cohort of the CHRYSALIS-2 study (NCT04077463) enrolled patients with EGFR-mutant NSCLC whose disease progressed on or after treatment with an EGFR TKI as last line of therapy (maximum of 3 prior lines)... Enrolled patients have received a median of 2 (range, 1-3) prior lines of therapy, including osimertinib (n=14), gefitinib (n=3), and afatinib (n=3)... Amivantamab in combination with lazertinib and chemotherapy yielded high overall response rates in patients who progressed on EGFR TKIs as prior line of therapy. The safety profile of the LACP regimen was consistent with the individual agents, with no evidence of new safety signals or additive toxicity."

Combination therapy • Fatigue • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • EGFR

Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis (ESMO Asia 2023) - P3 | "In the global, phase 3 PAPILLON study (NCT04538664), ami and carboplatin-pemetrexed (ami-chemo) significantly improved progression-free survival (PFS) vs chemo (data submitted to ESMO 2023) in treatment naïve patients (pts) with Ex20ins advanced NSCLC. Conclusions Ami-chemo demonstrated superior PFS vs chemo in Asian pts with a tolerable safety profile. These results were consistent with those of the overall population."

Clinical • EGFR exon 20 • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2 (ESMO 2024) - P3 | "Background: In the phase 3 MARIPOSA-2 study (NCT04988295), amivantamab (ami)-chemotherapy (chemo; carboplatin/pemetrexed) showed superior progression-free survival (PFS) vs chemo in patients (pts) with EGFR-mutant, advanced non-small cell lung cancer (NSCLC) after progression on osimertinib (osi; HR, 0.48; 95% CI, 0.36–0.64; P<0.001). Ami-chemo numerically improved OS and significantly prolonged post-progression outcomes vs chemo in EGFR-mutant, advanced NSCLC post-osi."

Clinical • Late-breaking abstract • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • EGFR

Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial (ESMO 2023) - P3 | "Background Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, plus carboplatin-pemetrexed (chemo) with and without lazertinib (laz), a CNS-penetrant, 3rd-gen EGFR TKI, have demonstrated antitumor activity in phase 1 studies. The impact of modifying the ami-laz-chemo regimen on safety and efficacy requires longer follow-up. Conclusions Ami-chemo and ami-laz-chemo improved PFS, ORR, and intracranial PFS vs chemo in EGFR-mutated advanced NSCLC after progression on osi and may represent a new standard of care."

Clinical • Late-breaking abstract • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2 (ELCC 2024) - P3 | "In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (HR, 0.48; P<0.001) in patients (pts) with EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). Conclusions Ami-chemo numerically prolonged TTSP vs chemo. More pts in the ITT population reported improved or stable functioning and absence of lung cancer-related symptoms for ami-chemo vs chemo in pts with EGFR-mutant advanced NSCLC after disease progression on osimertinib."

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-World Characteristics and Treatment Patterns of Cegfrm NSCLC Patients Receiving 2L+ Amivantamab Plus Chemotherapy (IASLC-WCLC 2026) - "In MARIPOSA-2, amivantamab plus carboplatin and pemetrexed (ACP) proved clinical benefit in reducing the risk of progression and represents the first targeted combination to significantly improve progression-free survival post-osimertinib. Vast majority of the patients were at advanced, metastatic disease at diagnosis, and were on average older and had higher ECOG performance statuses relative to the patients in MARIPOSA-2. Most patients initiating ACP remained on their index LOT during the observed follow-up, warranting continued follow-up of these patients and analysis of additional real-world outcomes."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821) (IASLC-WCLC 2026) - P2 | "A one-group chi-square test (one-sided alpha = 0.10) had 80% power to detect improvement from 50% (historical osimertinib - standard therapy when AMIGO-1 was designed) to 65% with 49 pts. Toxicity may have limited overall benefit. These findings support further evaluation of AMI+L+ pemetrexed, especially in poor prognostic pts."

Clinical • P2 data • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Pancreatitis • Solid Tumor • EGFR • TP53

Real-World Outcomes of NSCLC and Leptomeningeal Disease (IASLC-WCLC 2026) - "Targetable genomic alterations were identified in 89 patients (57%); the most common was classical EGFR mutations (n=52, 58%).Treatment with any systemic therapy after LMD diagnosis was associated with a longer OS, including treatment with platinum-based chemotherapy or pemetrexed (Table 1)...Among pts with EGFR mutations treated with osimertinib prior to LMD, subsequent EGFR TKI therapy was associated with longer OS, and subsequent amivantamab showed a trend toward improved OS (Table 1). Among pts without EGFR or ALK alterations, pts treated with immunotherapy after LMD diagnosis had a longer OS (Table 1). Conclusions : Although outcomes remain poor for patients with LMD, receipt of systemic therapy after LMD diagnosis was associated with improved OS, supporting continued use of systemic and molecularly guided treatments to optimize outcomes."

Clinical • IO biomarker • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • PD-L1

Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2 (IASLC-WCLC 2023) - P1 | "Introduction: Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity, plus lazertinib, a 3rd-generation EGFR tyrosine kinase inhibitor (TKI), have demonstrated antitumor activity in heavily pretreated patients with advanced non-small cell lung cancer (NSCLC) who have progressed on osimertinib (Bauml JCO 2021; 39:15_suppl, 9006, Shu JCO 2022; 40:16_suppl, 9006)...Here we present updated results with a longer duration of follow-up for the LACP (lazertinib, amivantamab, carboplatin, pemetrexed) regimen. The LACP cohort of the CHRYSALIS-2 study (NCT04077463) enrolled patients with relapsed/refractory EGFR-mutated advanced NSCLC whose disease progressed on or after treatment with an EGFR TKI as last line of therapy (maximum of 3 prior lines)... Among patients with EGFR-mutated advanced NSCLC who experienced disease progression on EGFR TKIs, amivantamab, lazertinib plus chemotherapy demonstrated meaningful and..."

Metastases • Fatigue • Febrile Neutropenia • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. (PubMed, N Engl J Med) - P3 | "The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, NCT04538664.)."

EGFR exon 20 • Journal • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON (ELCC 2024) - P3 | "In PAPILLON (NCT04538664), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo in patients (pts) with EGFR Ex20ins advanced NSCLC (Zhou NEJM 2023). Conclusions Ami-chemo significantly prolonged TTD and TTST vs chemo. Ami-chemo is the new first-line standard of care for EGFR Ex20ins-mutant advanced NSCLC."

Clinical • EGFR exon 20 • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1BB Bispecific Antibody Plus Chemotherapy in First-Line Advanced NSCLC (IASLC-WCLC 2026) - P2 | "The nsqNSCLC cohort received Opamtistomig (15 mg/kg) plus pemetrexed and carboplatin Q3W for 4-6 cycles, followed by maintenance with Opamtistomig plus pemetrexed. The sqNSCLC cohort received Opamtistomig plus paclitaxel and carboplatin Q3W, followed by Opamtistomig maintenance...While follow-up is limited, these results support further evaluation and suggest its novel mechanism could help define a new treatment approach in cancer immunotherapy. Updated results will be presented at WCLC 2026."

Bispecific • Clinical • Metastases • P2 data • Leukopenia • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor

Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR -mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study (IASLC-WCLC 2024) - P3 | "Among those, 72% (111/155) and 74% (173/233) initiated subsequent therapy, respectively, with carboplatin-pemetrexed being the most common first subsequent therapy across arms (amivantamab-lazertinib, 26% [29/111]; osimertinib, 28% [48/173]). At 24 months, 75% and 70% of patients were alive in the amivantamab-lazertinib and osimertinib arms, respectively; corresponding values at 36 months were 61% and 53%. Conclusions : Amivantamab-lazertinib continues to show a trend towards improved OS while also improving post-progression outcomes vs osimertinib, reaffirming amivantamab-lazertinib as a first-line standard-of-care for EGFR -mutated advanced NSCLC."

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis. (ASCO 2024) - P3 | "The phase 3 PAPILLON study (NCT04538664) investigated the combination of Ami and carboplatin/pemetrexed (ACP) vs. carboplatin/pemetrexed (CP) as first-line treatment in patients (pts) with advanced EGFR Exon20ins-mutated NSCLC. ACP demonstrated superior PFS compared to CP in Chinese pts. The safety profile was manageable and tolerable. These findings in Chinese subgroup were consistent with those of overall population and Asian subgroup."

Clinical • EGFR exon 20 • Metastases • Anemia • Hematological Disorders • Leukopenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • EGFR

Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy. (PubMed, Oncol Rep) - "Collectively, these findings identified Peme as a BRCA1‑stabilizing agent that enhances therapeutic response to radiation in TNBC. Pharmacological restoration of BRCA1 stability represents a promising strategy to overcome therapeutic resistance in BRCA1‑deficient or functionally compromised BC."

Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Triple Negative Breast Cancer • BRCA1 • HRD